| Prev Close | 12.15 |
| Open | 12.12 |
| Day Low/High | 11.81 / 12.14 |
| 52 Wk Low/High | 6.07 / 13.76 |
| Volume | 6.18M |
| Avg Volume | 10.87M |
Teva Pharmaceutical Industries Ltd. (TEVA)
11.92
0.23
1.89
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.10B |
| Market Cap | 12.57B |
| EPS | -0.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
I'm Adding This Pharma Company to My Top Stocks for 2020 List
Recro Pharma Inc., which makes drugs such as Ritalin LA for Novartis, looks healthy going into 2020.
Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter
Let's review the charts.
Jim Cramer: Here's Why the Market's So Feckless and Reactive
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
How to Extract Pretty Profits from Ugly Stocks
It's a process that involves harvesting gains by repeatedly writing call options against stocks steadily in decline.
China's Yuan Threat, Disney Volatility: Market Recon
The Chinese government has now demonstrated an ability to control the S&P 500, even at the risk of Chinese domestic capital flight.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The Oracle of Omaha Is Off His Game
Be careful backing Buffett right now, his biggest holdings show increasing profit pressure.
Jim Cramer: This Is Now an Emotional Market
When traders are flailing and investors are drowning, examples work best to illustrate what happens before a bottom is reached.
It Happens to the Best of Us!
If you get down on yourself in some of your trades and investments - check out the 2-3 year chart on Teva Pharmaceuticals . And consider that The Oracle of Omaha, Warren Buffett, owns over 43 million shares. I have been negative on fundamental groun...
How Low Can Teva Pharmaceutical Stock Go? Don't Fight the Tape
Do not try to pick a bottom on this stock.
Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
More Mud on Johnson & Johnson?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Upgrades, Downgrades, New Research
Before I jump on the radio, here's a quick list of upgrades, downgrades and new research coverage coming out of Wall Street this morning... - Hilltop Holdings upgraded to Overweight from Neutral at Piper Jaffray - Trex upgraded to Buy from Hold at S...
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Market Direction, Big Anniversary and a GE Play: Market Recon
There is still no news on China trade, so keep your chinstrap buckled and wear your flak jacket.
S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon
China trade discussions will continue to be a key driver in Wednesday's market action.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon
Do we have to run for the hills? Not necessarily.
I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side
Jim Cramer was bearish on TEVA.
Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'
Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.
Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release
Eli Lilly's excellent earnings weren't excellent enough.
Eli Lilly Offers Healthy Outlook to Kick Off November
The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.
Markets Are Headed For a More Difficult Environment: Market Recon
Santa is on his way... A lot of pressure on the jolly fellow this year.
